List of Excipients in Branded Drug VERZENIO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	VERZENIO	abemaciclib	0002-4483	CELLULOSE, MICROCRYSTALLINE	2031-09-28
Eli Lilly and Company	VERZENIO	abemaciclib	0002-4483	CROSCARMELLOSE SODIUM	2031-09-28
Eli Lilly and Company	VERZENIO	abemaciclib	0002-4483	FERRIC OXIDE RED	2031-09-28
Eli Lilly and Company	VERZENIO	abemaciclib	0002-4483	FERRIC OXIDE YELLOW	2031-09-28
Eli Lilly and Company	VERZENIO	abemaciclib	0002-4483	LACTOSE MONOHYDRATE	2031-09-28
Eli Lilly and Company	VERZENIO	abemaciclib	0002-4483	POLYETHYLENE GLYCOL	2031-09-28
Eli Lilly and Company	VERZENIO	abemaciclib	0002-4483	POLYVINYL ALCOHOL	2031-09-28

Verzenio Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Verzenio, Eli Lilly’s abemaciclib, is an immediate-release oral tablet with a conventional excipient system. The commercial opportunity is concentrated in generic Q1/Q2 development, excipient substitution, manufacturing optimization, supply-chain qualification and differentiated oral-solid-dose products. Because abemaciclib has dose-related gastrointestinal toxicity, an excipient strategy must protect dissolution and stability without implying that excipients can materially change the drug’s clinical tolerability absent new clinical evidence.

What excipients are used in Verzenio tablets?

Verzenio tablets contain a standard direct-compression or wet-granulation-type oral solid dosage platform built around lactose, microcrystalline cellulose and superdisintegrants. The FDA prescribing information identifies the following inactive ingredients:

Functional role	Verzenio excipient
Diluent and filler	Lactose monohydrate
Compressibility aid	Microcrystalline cellulose
Disintegrants	Croscarmellose sodium and sodium starch glycolate
Glidant	Silicon dioxide
Lubricant	Magnesium stearate
Film-forming system	Polyvinyl alcohol
Opacifier and coating aid	Titanium dioxide and talc
Color identification	Strength-specific iron oxide colorants

The tablets are available in 50 mg, 100 mg, 150 mg and 200 mg strengths. Color differentiation supports dose identification and medication-error reduction. The formulation is not an extended-release or enteric-release system. Patients take Verzenio with or without food, although grapefruit and grapefruit juice should be avoided because of CYP3A-mediated exposure concerns related to abemaciclib metabolism [1].

The label’s excipient disclosure establishes the commercial composition but does not, by itself, establish the scope of any formulation patent. Patent coverage must be evaluated against issued claims, Orange Book listings, prosecution history and later-filed patents.

How does Verzenio’s excipient system affect generic development?

The main generic objective is a formulation that matches the reference product’s critical quality attributes and demonstrates bioequivalence. An ANDA applicant does not generally need to use the same excipients in the same quantities, but substitutions can affect dissolution, tablet hardness, friability, disintegration, impurity growth and in-vivo performance.

Critical formulation risks

Abemaciclib generic development is likely to focus on four areas:

1. Dissolution matching.
   The balance between microcrystalline cellulose, croscarmellose sodium and sodium starch glycolate can materially affect disintegration and dissolution. Excessive lubricant, particularly magnesium stearate, can reduce wetting and slow release.

2. Blend uniformity.
   The active ingredient is present at relatively low levels in the 50 mg and 100 mg strengths compared with total tablet mass. Particle-size distribution, segregation control and blending order are central to content uniformity.

3. Moisture control.
   Lactose-containing formulations require control of water activity and storage humidity. Moisture can change tablet hardness, disintegration and impurity profiles.

4. Strength proportionality.
   A four-strength product line creates an opportunity for common granulation or blend platforms. The applicant must show that strength changes do not produce clinically relevant dissolution or exposure differences.

A lactose-free formulation could reduce intolerance concerns and simplify procurement for certain markets, but it would create additional formulation and bioequivalence work. Replacing lactose with mannitol, dibasic calcium phosphate or additional microcrystalline cellulose would require comparative stability and dissolution data and may alter tablet weight, compactibility and manufacturing economics.

What commercial opportunities exist for Verzenio excipient suppliers?

The largest near-term opportunity is not a novel excipient. It is supply and technical support for generic abemaciclib manufacturers.

1. Functional excipient supply

Excipient companies can target:

• High-purity microcrystalline cellulose with controlled particle-size distribution.
• Low-moisture lactose monohydrate.
• Direct-compression grades of croscarmellose sodium.
• Sodium starch glycolate with reproducible swelling performance.
• Low-peroxide, low-moisture silicon dioxide.
• Magnesium stearate with controlled specific surface area.
• Polyvinyl alcohol film-coating systems.
• Iron oxide colorants for strength-specific tablet identification.

Generic manufacturers will value lot-to-lot consistency more than a marginal reduction in nominal excipient price. A change in excipient grade can trigger process revalidation, dissolution comparability work and stability studies.

2. Dual sourcing and supply-chain resilience

A four-strength oncology product needs reliable excipient supply across commercial scale-up and post-approval manufacturing. Suppliers that offer qualified second sources, regional inventory and regulatory documentation can capture value through:

• Drug Master File support where applicable.
• United States Pharmacopeia and European Pharmacopoeia compliance.
• Nitrosamine, elemental impurity and residual-solvent statements.
• TSE/BSE and allergen documentation.
• Change-notification controls.
• Global regulatory support for the United States, European Union, Japan and emerging markets.

Excipient suppliers with manufacturing sites in multiple regions can reduce a generic sponsor’s change-control risk.

3. Process optimization

Excipient vendors can sell formulation-performance packages rather than commodity materials. Relevant services include:

• Tabletability and compactibility mapping.
• Design-of-experiments studies.
• Disintegration and dissolution optimization.
• Roller-compaction or wet-granulation process support.
• Lubrication-time optimization.
• Scale-up from laboratory to commercial compression.
• Stability modeling under accelerated conditions.

The commercial value is highest when the supplier’s grade allows a sponsor to reduce compression force, shorten granulation time or improve yield without sacrificing bioequivalence.

What formulation patents may affect Verzenio competition?

Formulation patent risk may arise from claims directed to:

• Abemaciclib compositions.
• Specific excipient combinations.
• Tablet manufacturing processes.
• Particle-size or solid-state characteristics.
• Dissolution profiles.
• Stability-improving formulations.
• Methods of treating breast cancer with specified dosing regimens.

The FDA-approved product is marketed under NDA 208716. The Orange Book should be used to identify patents listed against the NDA and their expiration dates, pediatric extensions and any patent-use codes [2]. Orange Book listing does not establish that every listed patent will survive validity or infringement challenges.

Patent and exclusivity framework

Issue	Strategic relevance
New chemical entity exclusivity	The five-year NCE period for the 2017 approval has expired
Regulatory exclusivity	Any remaining exclusivity must be assessed against current FDA records and supplements
Listed patents	May delay ANDA approval depending on patent status and litigation
Method-of-use patents	Can create labeling or carve-out issues for specific breast-cancer indications
Formulation patents	May create risk for otherwise conventional tablet formulations
Manufacturing patents	Can affect process selection even where the final tablet composition differs
Pediatric exclusivity	Requires confirmation from FDA records; it should not be assumed from the original approval

A generic sponsor should not rely on excipient substitution alone as a freedom-to-operate strategy. A formulation that uses different fillers or disintegrants can still infringe a claim covering the active ingredient, dosage form, particle characteristics, treatment method or manufacturing process.

When does Verzenio lose exclusivity and face generic entry?

Verzenio received FDA approval in September 2017. The five-year statutory NCE exclusivity period therefore expired in September 2022, subject to the exact approval date and any applicable pediatric extension [1,3].

Patent expiry, rather than NCE exclusivity, is the more important commercial variable for generic launch timing. ANDA applicants may file earlier under Paragraph IV certifications against listed patents. A Paragraph IV filing can create patent litigation and a potential 30-month stay of ANDA approval under the Hatch-Waxman framework, subject to statutory conditions and court outcomes [4].

Generic launch scenarios

Scenario	Commercial result
No Paragraph IV challenge	Entry waits for patent expiry or settlement-based approval
Paragraph IV challenge with no suit	FDA approval may proceed after statutory review requirements
Timely patent litigation	Approval may be stayed for up to 30 months unless the case resolves earlier
Successful invalidity or noninfringement decision	Earlier launch becomes possible
Settlement with licensed entry	Launch date depends on agreement terms
At-risk launch	Generic enters before final patent resolution and assumes damages and injunction risk

A generic entrant is likely to prioritize the 150 mg and 200 mg strengths if oncology prescribing patterns produce greater volume at those doses. A four-strength launch can still be commercially important because physicians may reduce or increase abemaciclib dose in response to toxicity, particularly diarrhea, neutropenia and fatigue.

What is the FDA and Orange Book status of Verzenio?

Verzenio is FDA-approved for HR-positive, HER2-negative advanced or metastatic breast cancer in specified treatment settings and for adjuvant treatment of high-risk, node-positive early breast cancer with a Ki-67 score requirement under the applicable labeling history [1].

The product is an oral tablet rather than a biologic. Biosimilar regulation is therefore not applicable. Competition will arise through ANDAs, authorized generic arrangements, licensing transactions and potentially reformulated products rather than through the 351(k) biosimilar pathway.

The Orange Book is relevant for:

• NDA identification.
• Listed patent numbers.
• Patent expiration dates.
• Pediatric exclusivity.
• Patent-use codes.
• Therapeutic-equivalence evaluations once ANDAs are approved.

FDA approval of an ANDA does not require the generic to reproduce Verzenio’s exact excipient quantities. It must meet applicable quality, labeling and bioequivalence requirements and address relevant patents and exclusivity.

What method-of-use and formulation opportunities exist?

Abemaciclib’s approved uses create possible lifecycle strategies, although each requires separate regulatory and patent analysis.

Dose-management formulations

A smaller tablet, dispersible tablet or alternative swallowability profile could target patients who experience dose reductions or difficulty swallowing. Such products would need clinical and regulatory support if they claim improved tolerability, adherence or pharmacokinetics.

Modified-release products

A modified-release abemaciclib product could seek lower peak concentrations or reduced dosing frequency. The commercial rationale is strong only if pharmacokinetic or clinical data show an advantage over the immediate-release tablet. Modified release would also create a new patent estate around polymer selection, release kinetics and manufacturing controls.

Combination products

Abemaciclib is frequently used with endocrine therapy. A fixed-dose combination with an aromatase inhibitor or fulvestrant could simplify administration, but combination-product development faces dose-ratio, stability, labeling and payer-coverage challenges. The commercial opportunity would be larger in settings where adherence and pill burden materially affect outcomes.

Special-population products

Pediatric development is not the primary commercial opportunity because approved use is concentrated in adult breast cancer. A liquid or dispersible formulation would require a defined clinical and adherence rationale rather than an excipient-only reformulation strategy.

How strong is the Verzenio excipient and formulation opportunity?

The opportunity is moderate for commodity excipient suppliers and stronger for suppliers offering formulation engineering, regulatory support and qualified second sourcing.

Opportunity	Market attractiveness	Main barrier
Standard excipient supply	Medium	Price competition and qualification requirements
Specialty direct-compression grades	Medium-high	Need to demonstrate process and dissolution benefit
Lactose-free reformulation	Medium	Bioequivalence and stability burden
Modified-release abemaciclib	High but uncertain	Clinical, regulatory and patent-development cost
Fixed-dose combination	Medium	Dose compatibility and market-access constraints
Film-coating systems	Medium	Limited differentiation unless process performance improves
Generic manufacturing platform	High	Patent, BE and scale-up risk
Excipient regulatory services	Medium-high	Requires global documentation and change-control support

The strongest defensible position is a technically differentiated excipient platform that reduces manufacturing variability or supports a non-infringing generic formulation. A new excipient alone is unlikely to create a durable commercial advantage unless it improves stability, dissolution, manufacturability or patient usability.

What litigation and settlement issues affect generic Verzenio entry?

The relevant litigation question is whether an ANDA applicant has filed a Paragraph IV certification against listed Verzenio patents and whether Lilly has initiated a timely infringement action. Settlement agreements may establish a license date, permitted manufacturing conditions, restrictions on launch timing or other commercial terms.

Public FDA labeling and Orange Book data do not establish the full litigation posture. Court dockets, complaints, claim-construction rulings, settlement filings and FDA correspondence must be reviewed separately for a current case-specific conclusion. Formulation developers should analyze both listed patents and unlisted process, composition and method-of-use rights.

How does Verzenio compare with competing CDK4/6 inhibitors?

Product	Active ingredient	Dosage form	Key formulation implication
Verzenio	Abemaciclib	Immediate-release tablet	Four strengths, conventional excipient platform
Ibrance	Palbociclib	Capsule and tablet presentations depending on market	More complex dosage-form history and formulation differentiation
Kisqali	Ribociclib	Tablet	Competes in overlapping HR-positive/HER2-negative breast-cancer indications

Verzenio has a commercial formulation advantage in dosing flexibility because it is supplied in four tablet strengths and is used continuously in many treatment settings. That advantage also increases manufacturing complexity and inventory requirements for generic entrants.

Key Takeaways

• Verzenio uses a conventional immediate-release tablet with lactose, microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, silicon dioxide, magnesium stearate and a film-coating system.
• Generic opportunity is driven by bioequivalence, excipient-grade control, manufacturing reliability and patent timing.
• NCE exclusivity expired in 2022, but listed patents and Paragraph IV litigation remain central to entry timing.
• Biosimilar competition does not apply because abemaciclib is a small-molecule drug.
• The best excipient opportunities involve controlled particle size, low moisture, dissolution performance, second sourcing and regulatory documentation.
• Lactose-free, modified-release and fixed-dose combination products offer lifecycle potential but require substantially more development than a standard ANDA.
• Excipient substitution does not independently eliminate infringement risk from active-ingredient, method-of-use, process or formulation claims.

FAQs About Verzenio Excipients and Commercial Strategy

Does Verzenio contain lactose?

Yes. Verzenio tablets contain lactose monohydrate as an inactive ingredient, according to the FDA prescribing information [1].

Can a generic version of Verzenio use different excipients?

Yes. An ANDA applicant may use different excipients if the product meets FDA quality and bioequivalence requirements and addresses applicable patent and exclusivity obligations.

Is Verzenio an extended-release tablet?

No. Verzenio is an immediate-release oral tablet.

Can an excipient company patent a generic Verzenio formulation?

Potentially. Patentability would depend on novelty, non-obviousness, written description, enablement and claim scope. A patent directed to a specific excipient combination or manufacturing process would not automatically provide freedom from patents covering abemaciclib or its therapeutic use.

Are biosimilars expected for Verzenio?

No. Abemaciclib is a small-molecule active ingredient regulated through the ANDA pathway, not the biologic biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Verzenio (abemaciclib) tablets, prescribing information. Eli Lilly and Company.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). FDA approves new treatment for certain breast cancers.
4. U.S. Food and Drug Administration. (2017). Guidance for industry: 180-day exclusivity when multiple first applicants are eligible for 180-day exclusivity.